Hansa Biopharma schedules Q3 2026 earnings call for November 11
Hansa Biopharma will release its financial results for the first nine months of 2026 on November 11, followed by a management conference call.
Lund-based biopharmaceutical company Hansa Biopharma has set November 11, 2026, as the date for the release of its interim report covering the period from January to September 2026. The announcement marks a key milestone in assessing the company's fiscal progress this year.
Management, including CEO Renée Aguiar-Lucander and CFO Adam Cutler, will lead a conference call at 14:00 CET on the same day. Joining them are CMO Richard Philipson and Maria Törnsén, COO and President U.S., who will present a comprehensive review of the quarterly financials and updates regarding the company’s product pipeline.
The presentation will be conducted in English and is open to investors and stakeholders interested in the company’s operational and financial developments.